IGY-110 is an IgY polyclonal antibody targeting the spike proteins of the coronavirus directly via intranasal delivery to the key site of coronavirus entry and infection. Enteric-coated capsules will also be used to help reduce virus activity in the gastrointestinal tract.
The intranasal delivery approach is supported by a recent major scientific publication in the journal Cell, where scientists from the University of North Carolina School of Medicine and the University of North Carolina Gillings School of Global Public Health found that SARS-Co-V2 infects and replicates in the nasal cavity to a greater degree than in cells lower down in the respiratory tract, including the lungs.
IGY-110 is presently in preclinical trials at Health Canada’s National Microbiology Lab in Winnipeg Manitoba.
Please contact us to learn more about IGY-110 or to explore partnership opportunities.